

MembranePlus[®]

Stimulate your *kinetic* understanding... Permeability | Binding | Metabolism | Transporters



What is MembranePlus™?

MembranePlus is an advanced, yet easy-to-use, modeling and simulation software program that unlocks important information from your *in vitro* permeability and hepatocyte assay studies. With MembranePlus, all relevant experimental and cellular processes, such as protein binding, lysosomal trapping, pH difference, shaking rate, paracellular permeability, cell viability, and carrier-mediated transport & metabolism, are integrated to simulate drug concentrations from *in vitro* cell-based/noncell-based assays and calculate the corresponding permeability & additional *in vivo* rate parameters. The combination of MembranePlus and GastroPlus[™] brings you closer to accurately predicting *in vitro* – *in vivo* extrapolation (IVIVE) of absorption (both passive and carrier-mediated) and systemic clearance/ distribution processes!

How can we use it?

For over 20 years, significant research has been devoted to *in vitro* permeability (e.g., Caco-2 assays) and hepatocyte systems, with several guidelines being published and all pharmacopeia describing appropriate methods for testing.

Unfortunately, these experiments are expensive, and since you don't have a lot of time or material available, how do you prioritize which compounds to test early in your project? Once you have identified a few promising leads, is your experimental design robust enough to capture all of the relevant information you need? And, after you collect the data and compile your apparent permeability or intrinsic clearance, are you certain you are not overlooking anything?

Enter MembranePlus™, the industry's leading mechanistic *in vitro* permeability & hepatocyte modeling software.

MembranePlus has several primary applications:

Simulation of in vitro permeability & hepatocyte concentrations

- Screen compound libraries and prioritize compounds for testing
- Predict various permeability (e.g., paracellular, transcellular) & hepatocyte (e.g., diffusional clearance, lysosomal trapping, biliary excretion) processes
- Estimate different intracellular concentrations, including:
 - o Membrane
 - o Cytosol
 - o Lysosome
- Assess impact of experimental variability on the predicted outcomes

Analysis of measured in vitro experimental data

- Identify paracellular vs. transcellular permeability values
- Calculate in vitro Km and Vmax for enzymes and transporters
- Determine the impact of lysosomal trapping
- Assess biliary excretion routes with sandwich hepatocyte assays
- Fit parameters to build a robust model and unlock important insight from the data


Who should be using it?

MembranePlus is going to be very helpful for:

- Users of GastroPlus[™] looking to better inform inputs (e.g., lysosomal trapping, diffusional clearances, biliary excretion) for more accurate *in vivo* absorption and systemic clearance/distribution predictions with the Advanced Compartmental Absorption and Transit (ACAT[™]) and PBPK models
- Discovery scientists looking to categorize compounds into high and low permeability classes
- DMPK researchers that focus on *in vitro* transporter/metabolism kinetic studies model your measured data to capture all relevant information from the expensive experiments you are running
- CROs which provide *in vitro* permeability (Caco-2, PAMPA, or MDCK) or hepatocyte services, to assist with the optimization of the experimental design for client studies

MembranePlus has default models describing several common in vitro systems:


- 1.) PAMPA (12 and 96 wells)
- 2.) Caco-2 (12, 24, and 96 wells)
- 3.) MDCK (12, 24, and 96 wells)
- 4.) NEW! Sandwich hepatocytes (6,12, 24, 48, and 96 wells)
- 5.) NEW! Suspended hepatocytes (6, 12, 24, 48, and 96 wells)



Of course, use MembranePlus to customize any cell-monolayer based in vitro system to mimic your in-house lab!


For the experiment, MembranePlus allows you to control the following during your simulations:

- 1.) pH in donor and receiver compartments
- 2.) Addition of albumin to donor or receiver compartments
- 3.) Shaking/stirring rates
- 4.) Volume of media in donor and receiver compartments
- 5.) Sampling protocols that may impact volume or drug concentrations, including:
 - a. Withdrawal of sample volume
 - b. Replacement of sample volume with blank buffer or original donor solution
 - c. Moving the insert to a different plate with blank buffer in receiver compartment
- 6.) Cell culture time
- 7.) Filter surface area
- 8.) Filter pore size and density
- 9.) Cell viability and density



What drug information is needed for the simulation?


Basic physicochemical properties (e.g., logP/logD, pKa(s), and molecular weight) can be defined through *in vitro* measurements or predicted from chemical structure (through ADMET Predictor[™]). If including enzymes or transporters in your assay, information about Vmax and Km needs to be entered (or can be "fitted" with measured concentration-time data from your permeability or hepatocyte studies).



Lysosomal Trapping - An important consideration

In MembranePlus, lysosomal trapping, a process which can impact a compound's distribution in tissues, can be studied in the simulations.


NEW! Fu Cell – this new output provides an estimate of Fu,Enterocytes for use in GastroPlus PBPK models. This improves the prediction of absorption & pharmacokinetics for compounds exhibiting lysosomal trapping and/or high binding in enterocytes causing extended Tmax values.




The Simulation Outputs - how does it look?

With MembranePlus, you can run the program in one of several modes:

• Single simulation: based on your drug properties (whether measured or predicted through ADMET Predictor™) and experimental setup, easily run a simulation to predict the time course changes in concentrations (e.g., apical, basolateral, cellular, or lysosomal).



• Parameter Sensitivity Analysis: during early drug development, researchers have a large number of compounds to evaluate and limited resources. With Parameter Sensitivity Analysis, quickly assess the impact of changes to certain properties (e.g., physicochemical or experimental) on critical endpoints. This can help guide your resource allocation plans and identify which experiments should be done next.



- Batch Simulations: quickly screen a library of compounds based on predicted permeability or run the same compound through a series of different Caco-2, PAMPA, MDCK, or hepatocyte experiments. Easily prioritize compounds in any way you like: from high to low permeability, based upon potential issues with lysosomal trapping, etc.
- **Optimization:** an important feature of MembranePlus which turns the program into a fitting routine. Using your measured concentration vs. time data, fit parameters to build more robust models and "learn" from your chemical series. Or, apply the feature to help design your *in vitro* permeability (Caco-2, PAMPA, MDCK) or hepatocyte experiment

Regardless of the mode in which you run MembranePlus, report-quality results can be easily generated and shared with others.

T2002

MembranePlusTM: A Tool to Study *In Vitro*/*In Vivo* **Fransport and Drug-drug Interaction**

Ke X. Szeto, Viera Lukacova, Walter S. Woltosz, and Michael B. Bolger Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA

PURPOSE

To develop a mechanistic mathematical model for analysis of *in vitro* permeability assays that accounts for all mechanisms contributing to beserved apparent permeability. passive paracellular and transcellular diffusion. Carrier-mediated transport, as well as drug accumulation in membranes and some intracellular compartments (e.g., lysosomes). The model was validated by analyzing the effect of competitive inhibition of P-gp by vinblastine on the apparent permeability of indinavir in Caco-2 monolayers.

METHODS


apical and basolateral administration of 50 µg/mL (81.5 µM) indinavir alone and co-administration of 50 µg/mL (81.5 µM) indinavir with 70 µM vinblastine [1]. The physicochemical properties of indinavir and indinavir with competitive inhibition of P-gp by vinblastine. The model MembranePlusTM (Simulations Plus, Inc.) was used to analyze the vinblastine were predicted by ADMET PredictorTM 6.0 (Simulations Plus, Inc.). The contribution of paracellular diffusion was estimated Carrier-mediated ransport was modeled with Michaelis-Menten kinetics. The indinavir transcellular diffusion and membrane accumulation were fitted to the indinavir-alone data. This basic model was then applied to simulate the inhibition of P-gp by vinblastine by fitting the Vmax/Km ratio for also includes various effects of major experiment-related parameters concentration-time profiles in donor and receiver compartments after P-gp Vmax/Km ratio, along with parameters accounting for passive (e.g, shaking rate, solvent pH, filter support and sampling effects). rom drug properties and the experimental setup.

1. Compound Property



Figure 2. MembranePlus compound tab. The program allows two ways of accounting for passive eliftision through cell membranes: (1) S+ model as listed in Eqn. 1 and 2; and (2) direct transport parameter entries for all neutral and charged species.

References: 115. Kapitza et al. European Journal of Pharmesuults and Biopharmesults 66, 2007, 146-158 125. Status et al. Carevand Physicany and Biophysican (1 St. 787, 552-7 214. Kabitro et al., Journal of Pharmesultas Sciences 67 (2), 1977, 552-3 214. Zhume and an improving a Chapter and Sciences 67 (1), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 452-7 214. Zhume a status curve of Pharmesultas Sciences 67 (10), 1986, 1977–204



2. Transporter Setup








Figure 3. MembranePlus Experimental Setup tab. The program considers major experiment-related parameters, such as shaking rate, apical volume, basolateral volume, fitter area, and fitter support permeability and etc. Sa in [1], 0.1 mL samples were drawn from both and basolaterial chambers at 0.5, 1, 1, 5, 3 and 5 hours.

4. Paracellular and filter permeability

Both paracellular and filter permeabilities are accounted for in the program. The detault paracellular model is the Zhimin model [4], which and the project and the project and the provident structure mean projected radius and the hydrodynamically equivalent sphere radius. The filter permeability calculation was applied from [5]. Therefore, the effective paracellular accounted to be provided to








Figure 3. 5-hour simulation of indinavir profiles after (a) apical administration of indinavir, (b) basolateral administration of indinavir, (c) apical administration of indinavir and vinblastine and (d) basolateral administration of indinavir and vinblastine. Red: apical concentration: blue: basolateral concentration; orange: lysosomal concentration; amount transported by P-pp transporter.

CONCLUSIONS

MembranePlus accurately simulated the results of *in vitro* experiments with respect to a variety of mechanisms affecting measured apparent permeability. It is a promising tool in drug research and development. By separating the system-specific from drug-specific parameters in description of drug permeation through the cell membranes it allows obtaining "clean" drug-specific propries (i.e. intracellular Km for efflux transporters) that will allow more direct *in vitro-in vivo* extrapolation and predictions of absorption and drug-drug interactions.



Case Study: In Vitro/In Vivo Transport Analysis

Ke X. Szeto, Viera Lukacova, John DiBella, Walter S. Woltosz, and Michael B. Bolger

Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA

2. Experimental Setup

PURPOSE

permeability assays that accounts for all mechanisms contributing to passive paracellular and and metabolism, as well as drug accumulation in membranes and To develop a mechanistic mathematical model for analysis of in vitro some intracellular compartments (e.g., lysosomes). The model was applied to analyze the effects of lysosomal trapping on the measured transcellular diffusion, ionization effects, carrier-mediated transport, apparent permeability: apparent permeability of propranolol. observed

Emil

1

1

METHODS

propranolol, ibuprofen, and testosterone alone data. This basic model was then applied to explore the effect of bafilomycin on MembranePlus TM (Simulations Plus, Inc.) was used to analyze the ibuprofen, and testosterone were predicted by ADMET PredictorTM 6.0 (Simulations Plus, Inc.). The contribution of paracellular diffusion accumulation in lysosomes. The model includes various effects of apical and basolateral administration of ibuprofen, testosterone and propranolol alone, as well as propranolol in the presence of bafilomycin [1]. The physicochemical properties of propranolol, properties and the diffusion and membrane/lysosomal accumulation were fitted to the change in propranolol the experimental setup (i.e., shaking rate, solvent pH, filter support, sampling effects, etc.) on measured apparent permeability. concentration-time profiles in donor and receiver compartments after experimental setup. Parameters accounting for passive transcellular each drug was estimated from drug and the subsequent ysosomal for

1. Compound Properties



Figure 1. MembranePlus compound tab. The program allows two ways of accounting for passive diffusion through cell membranes: (1) the S+ model as shown in Eqn. 1 and 2; and (2) direct transport parameter entries for all neutral and charged species.

 $P_{Filter} = \frac{\varepsilon_F * D * F(r/R_F)}{2}$ $F(x) \rightarrow \text{Renkin Function}$

> The membrane entrance (KI) and exit rates (Ko) are given by Eqn. 1 and 2, as modified from [2] and [3], where $P_{aci}P_{aci}$ are the octanolwater and membrane-water partition coefficients, and c, m, γ and δ are fitting coefficients.

where P_{para} and P_{Filter} are the paracellular and filter permeabilities, r is the molecular radius, R_r is the filter pore radius, ϵ_r is the filter pore radius, ϵ_r is the filter pore radius, ϵ_r is the filter pore radius.

the filter pore depth

$$k_i = rac{\gamma P_{max}}{\partial r_{max} + 1}, k_o = rac{\gamma}{\partial P_{max}}$$

 $P_{max} = c(P_{eet})^m$

Eqn. 2 Eqn. 1

References: [1]A. T. Hakkiman, JPRT 338, 2000, 882-802 [1]A. T. Hakkiman, JPRT 338, 2000, 882-802 [3] H. Kubinyi et al., Journal of Phrameoudcal Sciences 67 (2), 1877, 282-3

[4] H. Zhimin et al., Transactions of Tranjin University 1 (1), 1995, 42-47 [5] A. Adson et al., Journal of Pharmaceutical Sciences 84 (10), 1995, 1197-1204

2

and basolateral administrations of ibuprofen, testosterone and propranolol simultaneously (6 profiles). The fitted concentration-time model was then applied to co-administration of propranolol and bafilomycin, suggesting that bafiloimycin caused an increase in lysosomal pH from 4 to 5.5 (Figure 4), which resulted in a good match of propranolol concentration-time profiles measured in the The membrane transport model (c, m, γ and $\overline{\mathbf{o}}$) was fitted to apical profiles showed a good match to the experimental data (Figure 3). The overall R² for all the concentrations was over 0.9. The same presence of bafilomycin.




Figure 2. MembranePlus Experimental Setup tab. The program considers major experiment-related parameters, such as shaking rate, apical volume, basolateral volume, filter area, filter support permeability,

The unstirred layer thicknesses are automatically calculated after the

3. Diffusion Model

etc.

relevant experimental parameters are entered: shaking rate, apical and basolateral volumes, filter area. Therefore, in the current

program, the apical and basolateral departments are separated into a well-stirred layer and a diffusion layer. This diffusion layer is then calculation of diffusion across the layers according to Fick's Second

divided into a number of thinner sublayers to allow accurate


Law, where c is the concentration and D is the diffusion coefficient.

(Fick's Second Law)

 $=D\frac{\partial^2 c}{\partial x^2}$

8 Ot

Note that in (c), cytosol and lysosomal concentrations are overlapping. A similar match between simulated and observed profiles was obtained for Figure 3. Simulated (lines) and in vitro (squares) concentration-time profiles after apical administration of 1 µM (a) propranolol (b) ibuprofen and (c) testosterone. Simulated apical, basolateral, cytosol and lysosomal concentrations are shown in red, blue, yellow and orange respectively basolateral administration (data not shown).



Both paracellular and filter permeabilities are accounted for in the program. The default paracellular model is the Zhimin model [4], which accounts for the molecule's mean projected radius and the

4. Paracellular and filter permeability

nydrodynamically equivalent sphere radius. The filter permeability calculation was adopted from [5]. The total effective paracellular

permeability is given by

profiles after apical administration of 1 μM propranolol in the presence of 100 nm bifilomycin. (a) lysosomal pH set to be 4. (b) lysosomal pH set to respectively. A similar match between simulated and observed Figure 4. Predicted (lines) and in vitro (squares) concentration-time be 5.5. Simulated apical, basolateral concentrations are shown in red and profiles was obtained for basolateral administration (data not shown). blue,

CONCLUSIONS

1 LLL1

The second

 $- \Longrightarrow P_{para}^{\rm eff} = \frac{P_{para}P_{\rm Filter}}{P_{para} + P_{\rm Filter}}$

Prilter

Ppara where Peff _

1

prediction of absorption, but also other processes affecting drug distribution in different tissues (e.g., lysosomal trapping). MembranePlus has enabled the ability to analyze in vitro experiments with respect to the variety of mechanisms affecting measured apparent permeability. The current study shows that it is a promising tool in drug research and development for in vitro-in vivo extrapolation, not only in

simulations plus, inc.

Results

St Simulations Plus 42505 10th Street West • Lancaster, CA 93534 • USA • phone: +1 - 661-723-7723 • fax: +1 - 661-723-5524 SCIENCE + SOFTWARE = SUCCESs e-mail: info@simulations-plus.com • website: www.simulations-plus.com • NASDAQ: SLP